Copyright: ©Author(s) 2026.
World J Gastroenterol. Sep 14, 2026; 32(34): 119467
Published online Sep 14, 2026. doi: 10.3748/wjg.119467
Published online Sep 14, 2026. doi: 10.3748/wjg.119467
Figure 10 Integrated immune and metabolic actions of non-alcoholic fatty liver disease therapies on the spleen-liver axis.
Statins and other non-alcoholic fatty liver disease therapies act on monocytes and Kupffer cells, dampening cytokine output and reshaping immune-metabolic signaling across the spleen-liver axis[207-209]. FXR: Farnesoid X receptor; GLP-1RA: Glucagon-like peptide-1 receptor; IL: Interleukin; PPAR: Peroxisome proliferator-activated receptor; TNF-α: Tumor necrosis factor alpha.
- Citation: Tarantino G, Citro V. Liver-spleen axis: Deciphering a crucial crosstalk in non-alcoholic fatty liver disease progression and therapeutic implications. World J Gastroenterol 2026; 32(34): 119467
- URL: https://www.wjgnet.com/1007-9327/full/v32/i34/119467.htm
- DOI: https://dx.doi.org/10.3748/wjg.119467